1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Healthcare Information Services
JD Health International Inc.

JD Health International Inc.

JDHIF
JD Health International Inc.US flagOther OTC
5.85
USD
- -
- -
18.66BMarket Cap
JD Health International Inc.
JDHIF
(Other OTC)

Recent

price

5.85

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
1.78
2.61
3.47
8.78
9.91
15.04
17.14
18.51
23.22
Revenue per Share
0.06
0.07
-0.31
-7.8
-0.35
0.12
0.69
1.32
1.7
Basic EPS, GAAP
0.01
0.06
0.13
1.66
0.94
1.17
1.45
1.36
3.17
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.02
-0.03
-0.44
-8.43
-6.37
-6.24
-5.55
-4.21
-2.52
Book Value per Share
0.21
0.24
-0.15
17.76
12.87
13.68
15.11
16.91
18.38
Tangible Book Value per Share
3,127
3,127
3,127
2,209
3,095
3,107
3,124
3,143
3,163
Basic Weighted Avg Shares
5,553
8,169
10,842
19,383
30,682
46,736
53,530
58,160
73,441
Sales/Revenue/Turnover
4.62
3.76
4
1.81
-4.45
-0.1
1.31
2.54
5.37
Operating Margin (%)
3
6
7
27
63
141
227
215
280
Depreciation Expense
179
215
-972
-17,234
-1,074
380
2,142
4,162
5,375
Net Income, GAAP
30.25
29.82
- -
- -
- -
44.92
20.44
13.34
10.99
Effective Tax Rate (%)
3.22
2.63
-8.96
-88.92
-3.5
0.81
4
7.16
7.32
Profit Margin (%)
654
736
7,079
38,023
37,700
40,091
33,265
42,939
35,607
Working Capital
2
2
6
61
134
129
119
149
429
LT Debt
663
749
-459
39,251
39,855
44,785
49,370
55,241
60,073
Total Equity
- -
30.38
- -
- -
- -
-0.06
1.17
2.43
6.01
Return on Invested Capital (%)
- -
-310.67
- -
- -
- -
-1.97
-11.84
-27.77
-53.17
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
8.96%
8.75%
Free Cash Flow
- -
31.5%
133.85%
Net Income, GAAP
- -
71.56%
29.16%
Sales/Revenue/Turnover
- -
32.02%
26.28%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
53,530
2024
- -
- -
- -
- -
58,160
2025
- -
- -
- -
- -
73,441

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.69
2024
- -
- -
- -
- -
1.32
2025
- -
- -
- -
- -
1.7

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Cognetivity Neurosciences Ltd. (CGNSF)
CareCloud, Inc. (CCLDO)
CloudMD Software & Services Inc. (DOC.V)
Scienture Holdings, Inc. (SCNX)
Induction Healthcare Group PLC (INHC.L)
OneMedNet Corporation (ONMDW)
Business
JD Health International Inc engages in the provision of comprehensive online and offline healthcare products and services, including pharmaceutical and healthcare product retailing such as medicines, medical devices, nutritional supplements, and pet healthcare products; healthcare services including online consultation, chronic disease management, family doctor services, home care services, and medical escort; digital healthcare solutions for corporates and insurance companies; smart medical devices such as blood glucose meters, oxygen generators, and respiratory therapy devices; and online medical insurance payment and marketing services. The company operates primarily in China with expanding operations encompassing offline pharmacies and cross-border healthcare services connecting users with over 100 top global hospitals and specialists across countries including Switzerland, Japan, Thailand, and the United States. Founded in 2018 and headquartered in Beijing, JD Health has formed several strategic partnerships recently, including collaborations with multinational pharmaceutical companies such as Pfizer, GlaxoSmithKline, Sanofi, Bristol-Myers Squibb, Abbott, and Boehringer Ingelheim for expanded drug distribution, vaccination programs, chronic disease management platforms, and pet healthcare. It also signed a strategic cooperation agreement with INTCO Medical to develop high-end customized medical products and build a comprehensive medical protection ecosystem. In late 2024 and 2025, JD Health launched a global healthcare service platform facilitating direct referrals and remote consultations to international medical resources, and entered service cooperation agreements to enhance online sales and health management services. These latest moves signify JD Health's expansion from its core e-commerce-enabled pharmaceutical retail model into integrated digital and global healthcare services, leveraging technology and partnerships to enhance access to healthcare and innovative medical products. The company also continues to grow its offline pharmacy network and smart health device offerings to support an integrated healthcare ecosystem. This positions JD Health International Inc as a leading integrated healthcare service provider in China with increasing international outreach and a strong focus on innovation through partnerships and technology-driven medical service platforms.

Company News

APIChatGPT

  • seekingalpha.com

    JD Health International Inc. (JDHIF) Q2 2025 Earnings Call Transcript

  • seekingalpha.com

    JD Health International Inc. (JDHIF) Q4 2024 Earnings Call Transcript